KRAS and melanoma: In addition to inducing BRAF binding to CRAF in NRAS mutant cells, 885-A and sorafenib also induce this binding in WM1791c melanoma cells and in SW620 and HCT116 colorectal carcinoma cells (Figure 2C), all of which express mutant KRAS (Table S2).